Search
Incyte Corp
INCYAdd to Watchlist
114.660USD
+0.910+0.80%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
22.93BMarket Cap
15.71P/E TTM
More Details of Incyte Corp Company
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Incyte Corp Info
Ticker SymbolINCY
Company nameIncyte Corp
IPO dateDec 06, 1993
CEOMeury (Bill)
Number of employees2617
Security typeOrdinary Share
Fiscal year-endDec 06
Address1801 Augustine Cut-Off
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19803
Phone13024986700
Websitehttps://www.incyte.com/
Ticker SymbolINCY
IPO dateDec 06, 1993
CEOMeury (Bill)
Company Executives of Incyte Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.06M
-34.96%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
358.08K
+22.15%
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
143.53K
+1.14%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
142.57K
+1.15%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
90.60K
-28.11%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
76.94K
+2.13%
Mr. Thomas R. Tray
Mr. Thomas R. Tray
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
68.89K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
60.95K
+2.69%
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Independent Director
Independent Director
47.17K
+19.54%
Mr. Lee Heeson
Mr. Lee Heeson
Executive Vice President - Incyte, International
Executive Vice President - Incyte, International
38.04K
-0.29%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.06M
-34.96%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
358.08K
+22.15%
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
143.53K
+1.14%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
142.57K
+1.15%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
90.60K
-28.11%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
76.94K
+2.13%
FAQs
Who are the top five shareholders of Incyte Corp?
The top five shareholders of Incyte Corp are: Mr. Herve Hoppenot
How many institutions hold shares of Incyte Corp (INCY)?
As of 2026Q1, 1617 institutions hold shares of Incyte Corp, with a combined market value of approximately 209.33M, accounting for 104.84% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3757856.00.
What is the biggest source of revenue for Incyte Corp?
In 2026Q1, the JAKAFI revenues business generated the highest revenue for Incyte Corp, amounting to 3.09B and accounting for 60.15% of total revenue.
